| | | | | | | | | | |
|
| |
|
| Dockets Entered
On November 23, 2005
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1976N-0286
|
| Bovine Teat Dips
|
|
|
|
|
| 2000N-1663
|
| Investigational New Drugs: Export Requirements
|
|
|
|
|
| 2002N-0273
|
| Animal Proteins Prohibited in Ruminant Feed
|
|
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
|
|
| 2005D-0310
|
| Guidance for Industry on Gene Therapy Clinical Trials Observing Participants for Delayed Adverse Events
|
|
|
|
|
| 2005N-0349
|
| FDA Survey of Current Manufacturing Practices in the Food Industry
|
|
|
|
|
| 2005N-0410
|
| Prescription Drug User Fee Act (PDUFA): Public Meeting
|
|
|
|
|
| 2005P-0480
|
| Meloxicam, Orally Disintegrating Tablets, 7.5 mg and 15 mg is suitable for submission as an ANDA
|
|
|
|
|
| 1976N-0286
|
| Bovine Teat Dips
|
|
|
|
|
| ANS 13
|
| FDA/Office of Legislative Services
|
| Vol #:
|
| 1
|
|
|
|
|
| 2000N-1663
|
| Investigational New Drugs: Export Requirements
|
|
|
|
|
| NFR
1
|
| FDA
|
| Vol #:
|
| 1
|
|
|
|
|
| 2002N-0273
|
| Animal Proteins Prohibited in Ruminant Feed
|
|
|
|
|
| C 114
|
| Eligible
|
| Vol #:
|
| 17
|
|
|
|
|
| C 115
|
| L. Reiff
|
| Vol #:
|
| 17
|
|
|
|
|
| C 116
|
| R. Varner
|
| Vol #:
|
| 17
|
|
|
|
|
| C 117
|
| Eligible
|
| Vol #:
|
| 17
|
|
|
|
|
| C
118
|
| Pet Food Institute (PFI)
|
| Vol #:
|
| 17
|
|
|
|
|
| C 119
|
| J. Flores
|
| Vol #:
|
| 21
|
|
|
|
|
| C 120
|
| J. Packeco
|
| Vol #:
|
| 21
|
|
|
|
|
| C 121
|
| A. Gonzalez
|
| Vol #:
|
| 21
|
|
|
|
|
| C 122
|
| J. Hernandez
|
| Vol #:
|
| 21
|
|
|
|
|
| C 123
|
| Eligible
|
| Vol #:
|
| 21
|
|
|
|
|
| C 124
|
| R. Garcia
|
| Vol #:
|
| 21
|
|
|
|
|
| C 125
|
| A. Fuler
|
| Vol #:
|
| 21
|
|
|
|
|
| C
126
|
| Valley Proteins, Inc.
|
| Vol #:
|
| 21
|
|
|
|
|
| C 127
|
| L. Esh
|
| Vol #:
|
| 21
|
|
|
|
|
| C 128
|
| L. Martin
|
| Vol #:
|
| 21
|
|
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
|
|
| ANS
1
|
| HF- 1 to Malaysian Palm Oil Promotion Council
|
| Vol #:
|
| 10
|
|
|
|
|
| ANS
2
|
| HF- 1 to Asociacion Nacional de Cultivadores De Palma Africana (ANCUPA)
|
| Vol #:
|
| 10
|
|
|
|
|
| C
36
|
| Malaysian Palm Oil Promotion Council
|
| Vol #:
|
| 10
|
|
|
|
|
| C
37
|
| Asociacion Nacional de Cultivadores De Palma Africana (ANCUPA)
|
| Vol #:
|
| 10
|
|
| | | | | | | | |
|
|
|
| 2005D-0310
|
| Guidance for Industry on Gene Therapy Clinical Trials Observing Participants for Delayed Adverse Events
|
|
|
|
|
| C
3
|
| Cell Genesys, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005N-0349
|
| FDA Survey of Current Manufacturing Practices in the Food Industry
|
|
|
|
|
| C
2
|
| Procter & Gamble Company (P&G)
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005N-0410
|
| Prescription Drug User Fee Act (PDUFA): Public Meeting
|
|
|
|
|
| SUP
1
|
| Hyman, Phelps & McNamara, P.C.
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005P-0480
|
| Meloxicam, Orally Disintegrating Tablets, 7.5 mg and 15 mg is suitable for submission as an ANDA
|
|
|
|
|
| CP
1
|
| Camargo Pharmaceutical Services
|
| Vol #:
|
| 1
|
|
